These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16282723)

  • 1. [Genetic alterations and chemoresistance].
    Akiyama S
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1895-901. PubMed ID: 16282723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The new mechanisms and reversal of drug resistance].
    Akiyama S
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):1-8. PubMed ID: 12557697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
    Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A
    Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.
    Lee NH
    Anticancer Agents Med Chem; 2010 Oct; 10(8):583-92. PubMed ID: 21194402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
    Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
    Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer pharmacogenetics.
    Marsh S; McLeod HL
    Br J Cancer; 2004 Jan; 90(1):8-11. PubMed ID: 14710198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New reversing agents that target membrane transporters].
    Akiyama S
    Nihon Shokakibyo Gakkai Zasshi; 2004 Jan; 101(1):9-17. PubMed ID: 14763151
    [No Abstract]   [Full Text] [Related]  

  • 8. [Tailored therapy in gastrointestinal and hepatic cancer--toward ideal medicine through genomic science].
    Imai K; Yoshida Y
    Nihon Shokakibyo Gakkai Zasshi; 2004 Mar; 101(3):255-63. PubMed ID: 15065344
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet.
    Pander J; Guchelaar HJ; Gelderblom H
    Curr Opin Mol Ther; 2010 Dec; 12(6):654-61. PubMed ID: 21154157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
    Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
    Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of chemosensitivity in gastric cancer.
    Park DJ; Lenz HJ
    Curr Opin Pharmacol; 2006 Aug; 6(4):337-44. PubMed ID: 16777480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment.
    Shimoyama S
    J Gastroenterol Hepatol; 2009 Jun; 24(6):970-81. PubMed ID: 19638079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetic testing to predict serious toxicity from 5-fluorouracil (5-FU) for patients administered 5-FU-based chemotherapy for cancer.
    Technol Eval Cent Assess Program Exec Summ; 2010 Aug; 24(13):1-3. PubMed ID: 21114065
    [No Abstract]   [Full Text] [Related]  

  • 15. Scientists probe cancer cell resistance: new insights may help development of new drugs.
    Friedrich MJ
    JAMA; 2003 Sep; 290(11):1435-7. PubMed ID: 13129965
    [No Abstract]   [Full Text] [Related]  

  • 16. From genome to drugs: where do we stand?
    Schmidt C
    J Natl Cancer Inst; 2011 Jul; 103(13):996-7. PubMed ID: 21693728
    [No Abstract]   [Full Text] [Related]  

  • 17. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
    Salgado J; Zabalegui N; Gil C; Monreal I; Rodríguez J; García-Foncillas J
    Oncol Rep; 2007 Feb; 17(2):325-8. PubMed ID: 17203168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
    Bosch TM
    Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib-mediated inactivation of Akt regulates ABCG2 function in head and neck squamous cell carcinoma.
    Chu TS; Chen JS; Lopez JP; Pardo FS; Aguilera J; Ongkeko WM
    Arch Otolaryngol Head Neck Surg; 2008 Sep; 134(9):979-84. PubMed ID: 18794444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of multidrug resistance in the age of targeted therapy.
    Türk D; Szakács G
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):246-52. PubMed ID: 19333870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.